To our knowledge, this is the first report demonstrated that enhancer remodeling driven aberrant activation of NOTCH3 to enhance the expression of SLUG, which confers chemoresistance of NPC. The gene discussed is NOTCH3; the disease is nasopharyngeal carcinoma.